Antiaggregation Potential of Padina gymnospora against the Toxic Alzheimer’s Beta-Amyloid Peptide 25–35 and Cholinesterase Inhibitory Property of Its Bioactive Compounds

Balakrishnan Shanmuganathan, Dicson Sheeja Malar, Sethuraman Sathya, Kasi Pandima Devi*

Department of Biotechnology, Alagappa University (Science campus), Karaikudi- 630 004, Tamil Nadu, India

* devikasi@yahoo.com

Abstract

Inhibition of β-amyloid (Aβ) aggregation in the cerebral cortex of the brain is a promising therapeutic and defensive strategy in identification of disease modifying agents for Alzheimer’s disease (AD). Since natural products are considered as the current alternative trend for the discovery of AD drugs, the present study aims at the evaluation of anti-amyloidogenic potential of the marine seaweed Padina gymnospora. Prevention of aggregation and disaggregation of the mature fibril formation of Aβ25–35 by acetone extracts of P. gymnospora (ACTPG) was evaluated in two phases by Thioflavin T assay. The results were further confirmed by confocal laser scanning microscopy (CLSM) analysis and Fourier transform infrared (FTIR) spectroscopic analysis. The results of antiaggregation and disaggregation assay showed that the increase in fluorescence intensity of aggregated Aβ and the co-treatment of ACTPG (250 μg/ml) with Aβ25–35, an extensive decrease in the fluorescence intensity was observed in both phases, which suggests that ACTPG prevents the oligomers formation and disaggregation of mature fibrils. In addition, ACTPG was subjected to column chromatography and the bioactivity was screened based on the cholinesterase inhibitory activity. Finally, the active fraction was subjected to LC-MS/MS analysis for the identification of bioactive compounds. Overall, the results suggest that the bioactive compound alpha bisabolol present in the alga might be responsible for the observed cholinesterase inhibition with the IC50 value < 10 μg/ml for both AChE and BuChE when compared to standard drug donepezil (IC50 value < 6 μg/ml) and support its use for the treatment of neurological disorders.
Introduction

Alzheimer’s disease (AD), an age related devastating neurodegenerative disorder results in cognitive impairments such as decision-making, language and behavioral activities. In recent years, several etiological factors have been linked to AD pathology, which include Aβ peptide (Aβ) and τ protein aggregation, metal ion accumulation, oxidative stress and reduction in cholinergic neurotransmission [1, 2, 3]. Among the factors, the most hopeful approach is the usage of antiamyloidogenic agents which could prevent aggregation of Aβ peptides. A senile plaque (SPs) is one of the most important neuropathological hallmarks of AD, and the major constituent of SPs is beta-amyloid (Aβ), which accumulates in the outer surface of the neurons. Aβ is the product of proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase and γ-secretase [4]. Particularly, the accrual level of Aβ oligomers correlates with the severity of cognitive impairment in patients with AD and play a vital role in AD pathology. Many clinicopathological studies have demonstrated that the deposition of insoluble Aβ produces the aggregation of amyloid fibrils in brain parenchyma and cerebral blood vessels, which is one of the major hallmarks of AD [5]. Extracellular aggregates of Aβ was observed in AD patients, the most predominant one is Aβ1–40 or Aβ1–42; however, they also contain peptides with shorter sequences such as Aβ25–35 fragment containing a stretch of 11 full length amino acid residues. It forms itself β-sheet structure and produces similar effects to those produced by its parent sequence and has been found to be biologically active conferring toxicity to neurons [6]. Pike et al demonstrated that Aβ peptides that exist in an aggregated state are directly toxic to cultured neurons, while insoluble Aβ peptides lack direct toxicity. Aβ25–35 peptide, the biologically active fragment includes both a hydrophilic domain (25–28) that contains a putative β-turn site and a hydrophobic domain (29–35) essential for stable aggregation [7]. Some neuropathological studies have found that low-molecular weight of amyloid oligomers subsequently give rise to high-molecular weight amyloid oligomer, termed as soluble aggregation intermediates. After soluble aggregation formation, the intermediate further aggregates to form fibrils along with hyperphosphorylated tau protein, which forms senile plaques in the hippocampal region of the brain [8]. It is related to the level of cognitive impairment in AD and local distribution of amyloid burden is often correlated with changes in the cognitive functions [9, 10].

Several reports suggest that huge number of environmental factors along with the inherent properties of Aβ, collectively results in the deposition of Aβ aggregates. Although the involvement of its molecular mechanism in development and progression of AD is not clear, a critical role of Aβ is universally accepted [11]. Apart from forming plaques, the Aβ oligomers are also more effective as neurotoxins that cause disruption of neuronal synaptic plasticity, which suggest that, inhibition of Aβ oligomerisation might lead to novel therapeutic method for AD treatment [12, 13] Recent reports illustrated that oxidative stress also plays a significant role in AD pathogenesis and Aβ peptides have been proposed as a source of oxidative stress. Oxidative stress induced by Aβ leads to increased oxidative modification of proteins and lipids which in turn leads to impaired cellular function, cell death and consequently cognitive decline and AD pathology [14].

In recent times, bioactive compounds derived from natural sources are attracting increasing awareness in the search of new drugs for AD treatment. Seaweeds or marine algae possess essential polysaccharides with huge number of secondary metabolites that might have bioactive properties for their use as foods, pharmaceuticals and cosmeceuticals. These secondary metabolites from seaweeds have potentially significant therapeutic values and provide a great variety of biological compounds for sampling in the phase of drug discovery and development [15]. Based on this, the current study is mainly focused on the marine brown seaweed P. gymnospora.
for the detection of anti-amyloidogenic agents. *P. gymnospora* is known to possess a variety of valuable medicinal properties such as anti-cancer, anti-coagulant, anti-bacterial, anti-angiogenic and anti-adhesive activities [9, 16, 17, 18, 19]. Though *P. gymnospora* has been reported for its therapeutic potential to cure other human ailments, reports on its possible neuroprotective potential is not available. Consequently the objective of the work is designed to assess the anti-aggregation and disaggregation property of brown seaweed *P. gymnospora* against Alzheimer’s beta-amyloid peptide 25–35, which may provide a lead for the identification of novel therapeutic compounds with an ability to combat AD. In addition to pharmacological agents, extracts derived from natural source have bioactive potential and are used as a good candidate for AD treatment. Initial screening of the seaweed under study *P. gymnospora* which is densely inhabited in the Gulf of Mannar region, for anti-AD properties revealed that the acetone extract of *P. gymnospora* (ACTPG) possesses excellent antioxidant activity and cholinesterase inhibitory activity *in vitro*. The promising results of the preliminary studies prompted us to further extend the study by verifying its anti-amyloidogenic activities. The present study showed an insight into the bioactive compounds present in the alga, which might be responsible for the observed cholinesterase inhibition. The current study undoubtedly shows the antiaggregation and disaggregation potentials of *P. gymnospora*, which has also provided a novel bioactive compound Alpha-bisabolol, which can be used to combat AD.

**Materials and Methods**

**Chemicals**

AChE from Electric eel (Type-VI-S, EC 3.1.1.7, Sigma) and BuChE from horse serum (EC 3.1.1.8, MP Biomedicals) were used as enzyme source, acetylthiocholine iodide (ATCI) and butyrthiocholine iodide (BTCI) (Himedia laboratories, Mumbai, India) were used as substrates. 5,5'-Dithio-bis (2-nitrobenzoic) acid (DTNB) was procured from Himedia laboratories, Mumbai, India. Aβ<sub>25–35</sub> peptide was purchased from GenScript USA Inc. Thioflavin T (ThT) and L-carnosine was obtained from Sigma Aldrich Co. LLC. Alpha-bisabolol and caffeine were obtained from Alfa Aesar, UK. All the other reagents and chemicals used were of analytical grade.

**Preparation of seaweed extract**

**Collection and processing of seaweed samples.** Seaweed (*Padina gymnospora*) was collected from the intertidal region of Gulf of Mannar region, Tamil Nadu, and the species was identified according to the reference [20, 21]. The seaweed which was washed off the shore was collected for the experiments, for which permission is not required. We confirm that the field studies did not involve endangered or protected species. According to the method of Ratnasooriya et al the collected seaweeds were processed to remove the attached specimens on its surface [22]. The samples were then washed with tap water, distilled water and then with 70% alcohol to remove the adhered microflora. The processed seaweed was dried under shade and stored in an airtight zip-lock container. For extraction, 100 g of dried seaweed was packed in a Soxhlet apparatus by using Whatman No. 1 filter paper and extracted with respective solvents (1000 ml). The process of successive extraction was carried out for 6 h using different solvents (ranging from non polar to polar). After extraction, all the extracts were filtered by using Whatman No. 1 filter paper and subjected to dryness under reduced pressure in a vacuum desiccator. The dried extract was dissolved in distilled water containing less than 0.02% of methanol or Tween 20 as solvents and used for further analysis. The extraction procedures were done at a temperature less than 40°C to avoid thermal degradation of the compounds.
Antiaggregation and disaggregation assays

According to the method of Ramesh et al the anti-aggregation and disaggregation property of *P. gymnospora* was evaluated in two different phases [12]. In phase I, the inhibition of aggregate formation was assessed by using oligomers. Consequently, in phase II the disaggregation of the pre-formed fibrils were determined. Freshly prepared Aβ<sub>25-35</sub> (100 μM) monomer was incubated in Tris-HCl buffer pH 7.4 at 37°C for 20 h. However, after 20 h, an increase in fluorescence intensity was observed which represents the formation of oligomers. The acetone extract of *P. gymnospora* (ACTPG) (250 and 500 μg/ml) was added to the oligomers and subjected to incubation at 48 h for dose fixation. After fixing the optimum concentration of ACTPG, the Aβ<sub>25-35</sub> oligomers were incubated with/without ACTPG (250 μg/ml) for 20 h, 48 h, 96 h and 9 days respectively. In phase I, the freshly prepared Aβ<sub>25-35</sub> (100 μM) was incubated with ACTPG (250 μg/ml), and the aggregation pattern was evaluated by ThT assay with the aliquots taken from the incubation mixture at 20 h and 48 h respectively. Whereas in phase II, the freshly prepared Aβ<sub>25-35</sub> (100 μM) was incubated for 96 hours, for the formation of mature fibrils. After that, ACTPG (250 μg/ml) was co-incubated with the pre-formed fibrils, and the disaggregation pattern was evaluated by taking the aliquots of incubation mixture at 96 h and 9 days using Thioflavin T assay using the standard Galantamine (50μM) as a positive control. Additionally, microfluorescence assay and Fourier transform infrared analysis (FT-IR) were employed to further confirm the anti-aggregation and disaggregation property of *P. gymnospora*.

**Thioflavin T assay.** Thioflavin T-induced fluorescence changes were measured to quantify amyloid fibril formation by spectrofluorimeter (Microplate Analyzer) as described by [23]. Aliquots (20 μl) from the incubation mixtures of both the phases were added to 50 mM glycine—NaOH buffer (pH 8.5) containing 5 mM Thioflavin T in a final volume of 1 ml. Each sample was analyzed in triplicates, and the fluorescence intensities were measured at 450 nm (excitation) and 485 nm (emission) under time resolved fluorescence mode in Spectramax M3 reader (Molecular Devices). The background fluorescence emitted by ThT was subtracted from the values of all the samples.

**Microfluorescence assay.** About 2.5 μl aliquot of the fibrillated Aβ<sub>25-35</sub> peptide (100 μM) sample was diluted (1:2) with 5 mM thioflavin T in 50 mM glycine-NaOH buffer (pH 8.5) and transferred onto a slide. Fluorescent signals (488 nm) were then visualized by the Confocal Laser Microscope System (CLSM FV300, Olympus, Tokyo, Japan) and processed by Adobe Photoshop (Adobe Systems, Mountain View, CA, USA). The fluorescence intensity was visualized in each of three random fields of the sample.

**FT-IR.** Alterations in the structural characteristics of Aβ<sub>25-35</sub> peptide was analyzed through FTIR and the spectra were recorded in Nicolet iS5 FT-IR Spectrometer (Thermo Scientific, Marietta, GA, USA) using OMNIC software [24]. The Aβ<sub>25-35</sub> peptide (100 μM) were incubated with/without ACTPG (250 μg/ml) for 20 h, 48 h, 96 h and 9 days respectively. For analysis, a small portion of the incubated sample mixed with potassium bromide was scanned from 4,000–400 cm<sup>-1</sup> with a spectral resolution of 4 cm<sup>-1</sup>.

**Purification of ACTPG using column chromatography.** Freeze dried bioactive ACTPG (10 gm) was impregnated with silica gel 60–120 mesh and loaded onto silica gel (100 × 35 mm) column. The column was thoroughly washed with hexane and eluted with linear gradient of solvent of n-hexane, CLFM, EA, ACT, MET and WAT with increasing polarity. Fractions were collected, freeze dried and the bioactivity was screened based on antioxidant and cholinesterase inhibitory activity.

**LC-MS/MS analysis of ACTPG.** Freeze dried bioactive ACTPG samples were subjected to LC-MS/MS by using reverse phase C-18 column. The compounds were isolated with an acetonitrile/water (50:50) at a flow of 0.2 mL min<sup>-1</sup>. The column temperature was set to 25°C during
all the running and the injection volume was 15 μl. Mass spectra was performed with software (HYSTAR+ of control bruker) and the spectra was recorded in LC-MS/MS (Bruker microtof III). Electron spray ionization (positive mode) with full scan was used for analyzing the compound. The identity of the compound and its molecular mass from 50–3000 m/z was confirmed by comparing their m/z ratio with those on the stored library.

**AChE and BuChE inhibitory assay for identified compounds.** ChE inhibitory activities were measured using a modified 96-well microplate assay developed by [25]. Briefly, AChE/ BuChE (10 μl at 10 U/ml) solution was incubated with various concentrations of three different major compounds of *P. gymnospora* such as L-Carnosine, alpha bisabolol and Caffeine in 0.05 M Tris-HCl buffer (pH 8.0/7.4) for 45 min at room temperature (RT). After incubation, 125 μl of 3 mM DTNB was added and the total volume was made up to 300 μl with Tris-HCl buffer (pH 8.0/7.4). Enzyme activity was initiated by the addition of 50 μl of 15 mm ATCI/BTCI. The hydrolysis of ATCI and BTCI was monitored by the formation of the yellow 5-thio-2-nitrobenzoate anion at 405 nm for 3 min using Model 680 Microplate Reader (Bio Rad, California). Donepezil (10–50 μg/ml), the standard anti-cholinesterase drug was used as reference. AChE activity was expressed as U/mg of protein (1U = μmol of thiocholine iodide formed/min/mg protein). The experiments were done in triplicate and the results are represented as % of inhibition, which was calculated using the molar extinction coefficient of DTNB (ελ = 13,600 M⁻¹ cm⁻¹). Percentage of inhibition of AChE/BuChE was determined by comparison of rates of reaction of samples relative to the blank (Tris-HCl buffer) using the formula, where SA is the specific activity.

\[
\% \text{ of inhibition} = \left( \frac{(SA \text{ of control} - SA \text{ of test sample})}{SA \text{ of control}} \right) \times 100
\]

**Statistical analysis**

Statistical analysis was performed using SPSS 17.0 software package. The results of all the experiments were represented as mean ± SD of triplicates employed. Analysis of variance was performed by one-way ANOVA. Significant differences between control and treated groups were determined by Duncan’s multiple range tests and p value < 0.1 were regarded as significant. The IC_{50} value was determined for different bioactive compounds present in *P. gymnospora* using Probit analysis.

**Result and Discussion**

**Antiaggregation and disaggregation property of Aβ_{25-35} by acetone extract of *P. gymnospora* (ACTPG)**

The freshly prepared Aβ_{25-35} (100 μM) monomer was incubated in Tris-HCl buffer pH 7.4 at 37°C for 20 h to form oligomers. The ACTPG (250 and 500 μg/ml) was added to oligomers and subjected to incubation at 48 h for dose fixation. After fixing the optimum concentration of ACTPG, the Aβ_{25-35} oligomers were incubated with/without ACTPG (250 μg/ml) at different time intervals and the aliquots of 20 μl were drawn from the incubation mixture at 20 h, 48 h, 96 h and 9d respectively. Fujiwara et al reported that crude extracts of plants rich in polyphenolic content exhibits potent anti-amyloidogenic properties [26]. In 2012, Vauzour has demonstrated that plant based compounds are rich in polyphenol such as curcumin, rosmarinic acid, tannic acid, catechin and quercetin have an ability to inhibit the Aβ fibril formation *in vitro* [27]. Based on these observations, the present study was carried out to assess the inhibition of fibril formation by ACTPG under *in vitro* conditions using Thioflavin T assay and the results were further validated through confocal microscopy study and Fourier Transform Infrared (FTIR) spectroscopic analysis.
Many chemical ligands have been developed as Aβ aggregation inhibitors in recent years including Curcumin and scyllo-inositol [13, 28] but very few have progressed to clinical trials. Considering this disappointing situation, it is appropriate to search for alternative Aβ aggregation inhibitors among natural products. Some fungal and plant extracts have remarkable anti-AD activities in vitro and in vivo due to the inhibition of Aβ aggregation [13]. Durairajan et al reported that Salvinolic acid B (Sal B) derived from Salvia miltiorrhiza, a Chinese herbal medicine commonly used for the treatment of cardiovascular and cerebrovascular disorders, has been found to possess inhibitory effect on Aβ fibrillation and disaggregation of fibrils [29]. Such studies justify further research on natural products, which could identify lead compounds for AD treatment.

**Thioflavin T assay.** Thioflavin T assay was performed to assess the antiaggregation and disaggregation property of Aβ peptide [23]. The results of Thioflavin- T fluorescence assay was performed in two different phases at different time intervals (20 h, 48 h, 96 h and 9d) are shown in Fig 1. The results show that incubation of Aβ peptide at 37°C for 20 h the fluorescence intensity was less (3.21 ± 1.19 AU); however, at 48 h of incubation, the fluorescence intensity is slightly increased (3.57 ± 0.52 AU), which indicates the commencement of aggregation. Attractively, upon co-treatment of ACTPG (250μg/ml) with Aβ 25–35, an extensive decrease in the fluorescence intensity (1.68 ± 0.3 AU, 0.84 AU) was observed, which indicates that the extract prevents the formation of fibrils from oligomers in Phase I. In addition, ACTPG disaggregates the pre-formed fibrils in Phase II. A prominent increase in fluorescence from 96 h to 9 days was observed in Aβ 25–35 alone, and the observed fluorescence intensity was 4.67 ± 0.28 AU, 6.06 ± 0.47 AU respectively. The significant decrease in fluorescence intensity in ACTPG (3.95 ± 0.51 AU, 2.00 ± 1.13AU) and Galantamine (3.62 ± 0.55 AU, 2.86 ± 0.94 AU) treated groups indicate that the ACTPG and galantamine reduced β-sheet by preventing the fibrillation.

**Microfluorescence assay.** In microfluorescence assay, an increase in the fluorescence was observed in control group (Aβ 25–35) at 20 h, 48 h, 96 h and 9 days indicating the fibrillar

![Fig 1. Effects of ACTPG on Aβ 25–35 fibrillogenesis.](image-url)

**Fig 1. Effects of ACTPG on Aβ 25–35 fibrillogenesis.** Analysis of the deposited amyloid aggregates as assessed by thioflavin T (ThT) assays in Phase I (20, 48 h) & II (96 h & 9days). Quantitative effects of ACTPG on Aβ 25–35 fibrillogenesis by ThT assay showing the bar diagram of thioflavin-T fluorescence of Aβ 25–35 in the presence and absence of ACTPG. The emission spectrum of ACTPG and galantamine alone was subtracted, and emission data of peptide dispersions were normalized. Values are expressed as Mean ± SD (n = 3).

doi:10.1371/journal.pone.0141708.g001
formation. The results of Thioflavin T assay was further validated by CLSM analysis. The
CLSM analysis reveals that the peptide aggregation starts after 20 hours and it increases rapidly
at 48 hours with an enhanced fluorescence emission in control group. Co-treatment with
ACTPG possessed potent anti-aggregatory property of Aβ25–35 peptide, as observed by the
decreased fluorescence intensities (Fig 2A). Prevention of fibril formation from the oligomers
was visible by the smaller non aggregated form of peptides even after incubating at 96 hours. A
complete breakdown of the mature fibrils into smaller peptides was visible, and the extract was
able to hold the destabilization potential even after 9 days of incubation (Fig 2B). CLSM system
images (Fig 2A and 2B) confirmed that the aggregated forms of Aβ25–35 were visible in control
group at different time intervals, and furthermore, the inhibition of aggregation and disaggre-
gation Aβ fibrils was observed in extract-treated group. A similar inhibitory effect on Aβ25–35
aggregation was observed in galantamine-treated group. Therefore, the results of these experi-
ments indicate that ACTPG could be able to prevent fibril formation and also to disaggregate
Aβ fibrils even after the aggregation process was initiated. However, a marked decrease in fluo-
rescence was observed in ACTPG and Galantamine treated groups, which indicates the antiag-
gregation and disaggregation property of ACTPG on Aβ fibrils.

FTIR spectroscopic analysis of ACTPG on Aβ25–35 peptide. The anti-aggregation and
disaggregation potential of ACTPG was further evaluated through FTIR analysis. Among the
different spectroscopic techniques, IR spectroscopy has been widely used for the structural
characterization and analysis of peptides and proteins [24]. Although there are different IR
absorption bands, the amide I (1600–1690 cm⁻¹ C = O stretching) and amide II (1480–1575
cm⁻¹ CN stretching, NH bending) regions are the well-known vibrational IR bands, which are
used particularly to reveal the conformational changes of peptides and proteins. Aβ25–35 exhib-
ite maximum absorbance at 1600 cm⁻¹, at 20 and 48 h, while the extract treated groups
showed reduction in absorbance similar to the standard galantamine, which illustrates that extract prevents the formation of fibrils from oligomers. In addition, at 96 h and 9 days, increase in absorbance was observed at 1600 cm$^{-1}$ in A$\beta$ treated groups, whereas no such shift was observed in extract-treated groups, which indicates the disaggregation property of extract.

Results of FTIR analysis (Fig 3) suggests that ACTPG restores the alteration in the conformational state of A$\beta_{25-35}$ in 20 h, 48 h, 96 h and 9 days by preventing the aggregation process.

Fig 3. (A) Inhibitory effects of ACTPG on the transformation of secondary structure of A$\beta_{25-35}$ by FT-IR. The secondary structure of A$\beta_{25-35}$ was followed by observing the amide I and amide II regions by FT-IR at different time intervals in phase I, which are the well-known vibrational IR bands particularly used to reveal the conformational changes of peptides and proteins. FTIR spectrum of A$\beta_{25-35}$ (100 $\mu$M) exhibited maximum absorbance at 1600 cm$^{-1}$, at 20 and 48 h in phase I, while the ACTPG treated groups showed reduction in absorbance similar to the standard galantamine, which illustrates that ACTPG prevents the formation of fibrils from oligomers. (B) Inhibitory effects of ACTPG on A$\beta_{25-35}$ peptide by FT-IR. The secondary structure of A$\beta_{25-35}$ was followed by observing the amide I and amide II regions by FT-IR at different time intervals in phase II, which are the well-known vibrational IR bands particularly used to reveal the conformational changes of peptides and proteins. In phase II (96 h and 9 days) FTIR spectrum exhibited increase in absorbance at 1600 cm$^{-1}$ in A$\beta$ treated groups, whereas no such shift was observed in ACTPG-treated groups, which indicates the disaggregation property of ACTPG.

doi:10.1371/journal.pone.0141708.g003
Bioactivity guided fractionation of ACTPG. Bioactive fractions were eluted with linear gradient of solvent with increasing polarity and 18 fractions (F1-F18) were collected and subjected to cholinesterase inhibition assay.

LC-MS/MS analysis for identification of active fraction of ACTPG. Bioactivity guided fractionation of ACTPG was carried out to isolate and identify the active compound responsible for the neuroprotective effect. Recent report on GC-MS analysis of ethylacetate extract of P. gymnospora.
gymnospora showed the presence of fucosterol as one of the major component. The identified compound fucosterol has been observed to possess several biological properties including antioxidant, cytotoxic, anti-diabetic and acetylcholinesterase (ACE) inhibitory activities [30]. The present study primarily focused on the detection of anti-amyloidogenic agents from the marine brown seaweed P. gymnospora. The in vitro anti-cholinesterase assay was employed to screen the bioactivity for collected fractionations. Among the 18 fractions, fraction eluted with Ethyl acetate: Methanol (9:1) showed highest cholinergic inhibitory effect, which was subjected to LC-MS/MS analysis. The identity of the compound and its molecular mass was confirmed by comparing their m/z ratio with those on the stored library and the results are tabulated in Table 1. LC-MS/MS analysis (Fig 7) showed the presence of dipeptide L-Carnosine, essential oil alpha-bisabolol, narcotic pain reliever Propoxyphene, central nervous system (CNS) stimulant Caffeine, plasticizer Dibutyl phthalate, herbicide Foramsulfuron and a human metabolite D-mannitol 1-phosphate in active fraction of ACTPG. Among the different compounds, essential oil alpha-bisabolol has been reported for several pharmacological properties ranging from anti-inflammatory to anticancer activities and also reported to restore the redox balance by antagonising oxidative stress [31]. The bioassay was carried out to screen the bioactive compounds present in ACTPG such as L-Carnosine, Caffeine, and alpha-bisabolol for evaluating its neuroprotective effect.

![BuChE inhibition assay](image)

**Table 1.** LC-MS/MS profile of ACTPG showing the presence of bioactive compounds.

| SL. NO | COMPOUND NAME         | MOLECULAR MASS |
|-------|-----------------------|----------------|
| 1     | L-Carnosine           | 227.18         |
| 2     | Alpha bisabolol       | 223.07         |
| 3     | Propoxyphene          | 340.25         |
| 4     | Caffeine              | 192.12         |
| 5     | Dibutyl phthalate     | 279.16         |
| 6     | Foramsulfuron         | 453.35         |
| 7     | D-mannitol 1-phosphate| 263.06         |

doi:10.1371/journal.pone.0141708.t001
Determination of ChE inhibitory property of compounds analyzed through LC-MS/MS. AChE is also involved in secondary cholinergic functions by promoting Aβ (amyloid-beta) deposition in the form of senile plaque or neurofibrillary tangles, which is considered to be an important hallmark for the progression of AD [32]. Inhibition of AChE not only plays a key role in enhancing the cholinergic neurotransmission in the brain, but also aids in reducing the aggregation of β-amyloid, the key factor in AD. On the other hand, the enzyme butyrylcholinesterase (BuChE) acts as a co-regulator of cholinergic neurotransmitter by hydrolyzing ACh in synaptic cleft [33]. Level of BuChE in AD brain was found to be elevated by two fold, which in turn enhanced the neurotoxicity of neuritic plaques [34]. Hence inhibition of AChE and BuChE is considered as a promising approach for the treatment of AD. The results (Figs 8 and 9) indicate that, among the different treatment groups [treated with the compounds L-carnosine, caffeine, alpha-bisabolol alone or in combinations of alpha bisabolol & L-carnosine (1:1) and alpha bisabolol & caffeine (1:1)], alpha-bisabolol alone treatment possessed a maximum cholinergic inhibitory activity, with the IC50 value < 10 μg/ml for both AChE(87%) and BuChE(66%) and showed significant inhibition for both AChE and BuChE (p<0.1) at 50 μg/ml respectively. Further, standard drug donepezil (IC50 value < 6 μg/ml) and the compound of our interest, alpha-bisabolol displayed a significant inhibition on ChE when compared to the previously reported compounds L-Carnosine and Caffeine [35, 36]. Inhibition of AChE and BuChE plays a major role in reducing the aggregation pattern of β-amyloid, which is an important key factor in AD pathology. The present study clearly indicates that alpha-bisabolol possibly plays a substantial role by modulating the amyloidogenic properties of Aβ. Finally we conclude that, alpha-bisabolol could be used as a potent anti-amyloidogenic drug for AD treatment.
Conclusion

In the present study, we have attempted to isolate multipotent drug from *P. gymnospora* to combat AD. Initial study was carried out using cell free *in vitro* system including anti-aggregation and disaggregation assays of Aβ peptide. The results of our anti-Aβ aggregation studies...
confirm that ACTPG exhibits anti-amyloidogenic effects. Since ACTPG acts as multifunctional agent exhibiting antiaggregation and disaggregation of Aβ fibrils, it can act as a potent drug to combat the multiple targets of AD. The most probable reason for their potential of antiaggregation property might be related to the presence of alpha bisabolol. Thus, the current study for the first of its kind unveils the neuroprotective potential of alpha-bisabolol from *P. gymnospora*, as well as its suitability as a novel and alternative bioactive molecule to combat AD. Further studies on alpha-bisabolol are underway to decipher their anti-amyloidogenic property against AD.

**Acknowledgments**

KPD wishes to thank DST, India, for offering Major Research Grant (DST No: SR/S0/AS-22/2012). BS wishes to thank DST for providing fellowship in the form of project fellow. The authors also gratefully acknowledge the use of the Bioinformatics Infrastructure Facility, Alagappa University funded by the Department of Biotechnology, Ministry of Science and Technology, Government of India (No. BT/BI/25/015/2012).

**Author Contributions**

Conceived and designed the experiments: KPD BS. Performed the experiments: BS DSM SS. Analyzed the data: KPD BS DSM. Contributed reagents/materials/analysis tools: KPD. Wrote the paper: BS KPD.

**References**

1. Mathew M, Subramanian S (2014) In vitro evaluation of anti-Alzheimer effects of dry ginger (Zingiber officinale Roscoe) extract. Indian J Exp Biol 52:606–12. PMID: 24956891
2. Liu Q, Kou JP, Yu BY (2011) Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-kB activation. Neurochem Int 58:119–125. PMID: 21078355
3. Galimberti D, Scarpini E (2011) Disease-modifying treatments for Alzheimer’s disease. Ther Adv Neurol Disord 4: 203–216. doi: 10.1177/1756285611404470 PMID: 21765871
4. Selkoe DJ (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer’s disease. Trends Cell Biol 8:447–453. PMID: 9854312
5. Haass C, Hung AY, Schlossmacher MG, Oltersdorf T, Teplow DB, et al. (1993) Normal cellular processing of the β-amyloid precursor protein results in the secretion of the amyloid β peptide and related molecules. Ann N Y Acad Sci 695: 109–116. PMID: 8239267
6. Pryor NE, Moss MA, Hestekin CN (2012) Unraveling the early events of amyloid-β protein (Aβ) aggregation: techniques for the determination of Aβ aggregate size. Int J Mol Sci 13:3038–72. doi: 10.3390/ijms13033038 PMID: 22489141
7. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW (1995) Structure-activity analyses of β-amyloid peptides: contributions of the Aβ 25–35 region to aggregation and neurotoxicity. J Neurochem 64, 253–265. PMID: 7798921
8. Ghahremanitamadon F, Shahidi S, Zargooshnia S, Nikkhah A, Ranjbar A, Soleimani Asl S (2014) Protective effects of Borago officinalis extract on amyloid β-peptide (25–35)-induced memory impairment in male rats: a behavioral study. Biomed Res Int
9. Cummings BJ, Cotman CW (1995) Image analysis of β-amyloid load in Alzheimer’s disease and relation to dementia severity. Lancet 346:1524–1528. PMID: 7491048
10. Nielson KA, Cummings BJ, Cotman CW (1996) Constructional apraxia in Alzheimer’s disease correlates with neuritic neuropathology in occipital cortex. Brain Res 96: 284–293.
11. Ittner LM, Gotz J. Amyloid-β and tau-a toxic pas de deux in Alzheimer’s disease (2011) Nat Rev Neurosci 12: 65–72. doi: 10.1038/nrm2967
12. Ramesh BN, Indi SS, Rao KSJ (2010) Anti-amyloidogenic property of leaf aqueous extract of Caesalpinia cristata. Neurosci Lett 475:110–4. doi: 10.1016/j.neulet.2010.03.062 PMID: 20356566
13. Wu H, Zhang F, Williamson N, Jian J, Zhang L, Liang Z, et al. (2014) Effects of Secondary Metabolite Extract from *Phomopsis occulta* on β-Amyloid Aggregation. Plos One 9 (10) e109438. doi: 10.1371/journal.pone.0109438 PMID: 25275648
14. Tamagno E, Guglielmotto M, Mon Tamagno E, Guglielmotto M, Monteleone D, Vercelli A et al. (2012) Transcriptional and post-transcriptional regulation of β-secretase. IUBMB Life 64: 943–50. doi: 10.1002/iub.1099 PMID: 23180460

15. Choi EY, Hwang HJ, Kim IH, Nam TJ (2009) Protective effects of a polysaccharide from Hizikia fusiformis against ethanol toxicity in rats. Food Chem Toxicol 47:134–9. doi: 10.1016/j.fct.2008.10.026 PMID: 19026708

16. Joshi NVM, Srisudha S (2012) Biochemical characterization, haemagglutinating activity and cytotoxic activity of Padina gymnospora (Kutzing) Sonder. Int J Bio Pharm Res 3(6): 956–961.

17. Kayalvizhi K, Vasuki S, Anantharaman P, Kathiresan K (2012) Antimicrobial activity of seaweeds from the Gulf of Mannar. Int J Pharm App 3:306–314.

18. Mayalen Z, Daniel R, Yolanda F (2007) Antioxidant activities in tropical marine macroalgae from the Yucatan Peninsula, Mexico. J Appl Phycol 19: 449–458.

19. Chander MP, Veeraragavam S, Vijayachari P (2014) Antimicrobial and Hemolytic activity of seaweed Padina gymnospora from South Andaman, Andaman and Nicobar Islands of India. Int J Curr Microbiol App Sci 3:364–369.

20. Oza RM, Zaidi SH (2003) A Revised Checklist of Indian Marine Algae, Central Salt and Marine Chemicals Research Institute, Bhavnagar, India pp. 1–296.

21. Krishnamurthy V, Joshi HY (1970) A Check List of Indian Marine Algae, Central Salt and Marine Chemicals Research Institute, Bhavnagar, India pp. 1–36.

22. Ratnasororia WD, Premakumara GA, Tillerkarratne LMV (1994) Postcoital contraceptive activity of crude extracts of Srilankan marine red algae, Contraception 50:291–298. PMID: 7805379

23. Munoz-Ruiz P, Rubio L, Garcia-Palomero E, Dorrorsoro I, del MonteMillan M, Valenzuela R, et al. (2005) Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer’s disease. J Med Chem 48: 7223–7233. PMID: 16279781

24. Szabó Z, Klement E, Jost K, Zarándi M, Sós K, Penke B (1999) An FT-IR study of the beta-amyloid conformation: standardization of aggregation grade. Biochem Biophys Res Commun 19:297–300.

25. Eilman GL, Courtney KD, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology 7: 88. PMID: 13726518

26. Fujiwara H, Tabuchi M, Yamaguchi T, Iwasaki K, Furukawa K, Sekiguchi K, et al. (2009) A traditional medicinal herb Paonia suffrutcosa and its active constituent 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose have potent anti-aggregation effects on Alzheimer’s amyloid beta proteins in vitro and in vivo. J Neurochem 109: 1648–1657. doi: 10.1111/j.1471-4159.2009.06069.x PMID: 19457099

27. Vauzour D (2012) Dietary Polyphenols as Modulators of Brain Functions: Biological Actions and Molecular Mechanisms Underpinning Their Beneficial Effects. Oxid Med Cell Longev Article ID 914273, 16 pp., doi: 10.1155/2012/914273

28. Sun Y, Zhang G, Hawkes CA, Shaw JE, McLaurin J, et al. (2008) Synthesis of scylo-inositol derivatives and their effects on amyloid beta peptide aggregation. Bioorg Med Chem 16: 7177–7184. doi: 10.1016/j.bmc.2008.06.045 PMID: 18635602

29. Durairajan SSS, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, et al. (2008) Salvianolic acid B inhibits Aβ fibril formation and disaggregates preformed fibrils and protects against Aβ induced cytotoxicity. Neurochem Int 52:741–50. PMID: 17964692

30. Murugan K, Iyer VV (2014) Antioxidant Activity and Gas Chromatographic-Mass Spectrometric Analysis of Extracts of the Marine Algae, Caulerpa peltata and Padina gymnospora. Indian J Pharm Sci 76:548–52. PMID: 25593390

31. Kamatou GPP, Viljoen AM (2010) A review of the application and pharmacological properties of α-bisabolol and α-bisabolol-rich oils. J Am Oil Chem Soc 87:1–7.

32. Rees T, Hammond PI, Sorq H, Youkpin S, Brimjoi S (2003) Acetylcholinesterase promotes beta-amylase plaques in cerebral cortex. Neurobiology of Aging 24:777–787. PMID: 12927760

33. Mesulam MM, Guillotet A, Shaw P, Levey A, Duysen EG, Lockridge O (2002). Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110:627–639. PMID: 11934471

34. Andrew Reid G, Darvest S (2015) Butyrylcholinesterase-Knockout Reduces Brain Deposition of Fibrillar B-Amyloid in an Alzheimer Mouse model. Neuroscience 298: 424–435. PMID: 25931333

35. Hipkiss AR(2007) Could carnosine or related structures suppress Alzheimer's disease? J Alzheimers Dis 11:229–40. PMID: 17522447

36. Arendash GW, Cao C (2010) Caffeine and coffee as therapeutics against Alzheimer’s disease. J Alzheimers Dis doi: 10.3233/JAD-2010-091249